View Older Stories View More Recent Stories

Mar 13, 2019 07:07AM Regeneron (REGN) and Sanofi (SNY) to Present New Praluent Data at ACC
Mar 13, 2019 07:00AM Regeneron and Sanofi to Present New Praluent® (alirocumab) Data at ACC.19
Mar 12, 2019 11:02PM Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2019 with Innovative Ideas on Exoplanets, HIV and a Classic Math Problem
Mar 12, 2019 09:56PM Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2019 with Innovative Ideas on Exoplanets, HIV and a Classic Math Problem
Mar 12, 2019 11:36AM FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents
Mar 11, 2019 03:45PM Regeneron (REGN) Announces FDA Approval of Dupixent for Moderate-to-severe Atopic Dermatitis in Adolescents
Mar 11, 2019 03:45PM FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents
Mar 11, 2019 03:44PM FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents
Mar 11, 2019 01:00AM New Genetic Data from Regeneron and GSK on 50,000 UK Biobank Participants Made Available to Global Health Research Community
Mar 8, 2019 04:01PM Regeneron Announces Upcoming Investor Conference Call
Mar 8, 2019 05:56AM Sanofi (SNY), Regeneron (REGN) Report FDA to Undertake Priority Review of Dupixent (dupilumab) for Adults with Inadequately Controlled Severe Chronic Rhinosinusitis with Nasal Polyps
Mar 8, 2019 01:02AM Sanofi: FDA to undertake priority review of Dupixent® (dupilumab) for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps
Mar 8, 2019 01:00AM Sanofi: FDA to undertake priority review of Dupixent® (dupilumab) for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps
Mar 8, 2019 12:59AM FDA to Undertake Priority Review of Dupixent® (dupilumab) for Adults with Inadequately Controlled Severe Chronic Rhinosinusitis with Nasal Polyps
Mar 1, 2019 08:38AM Regeneron (REGN), Sanofi (SNY) Report CHMP Recommends Approval of Dupixent (dupilumab) for Asthma Indication
Mar 1, 2019 08:35AM CHMP Recommends Approval of Dupixent® (dupilumab) for Asthma Indication
Mar 1, 2019 08:14AM Sanofi: CHMP recommends approval of Dupixent® (dupilumab) for asthma indication
Mar 1, 2019 08:13AM Sanofi: CHMP recommends approval of Dupixent® (dupilumab) for asthma indication
Mar 1, 2019 06:59AM New Analyses to Be Presented at AAD for Dupixent® (dupilumab) and the Burden of Atopic Dermatitis
Feb 25, 2019 05:22PM Regeneron and Sanofi Strongly Disagree with Verdict Upholding Three of Five Amgen U.S. Patent Claims Relating to PCSK9 Antibodies
Feb 25, 2019 04:58PM Amgen (AMGN) Confirms Jury Upholds Its Patents on Repatha
Feb 25, 2019 12:46PM Sanofi: Positive results presented from two Phase 3 trials of Dupixent® (dupilumab) in severe chronic rhinosinusitis with nasal polyps
Feb 25, 2019 12:45PM Sanofi: Positive results presented from two Phase 3 trials of Dupixent® (dupilumab) in severe chronic rhinosinusitis with nasal polyps
Feb 25, 2019 12:45PM Regeneron (REGN) Says Positive Results Presented from Two Phase 3 Trials of Dupixent in CRSwNP
Feb 25, 2019 12:44PM Positive Results Presented from Two Phase 3 Trials of Dupixent® (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Feb 15, 2019 04:42PM U.S. and EU Patent Office Decisions Invalidate Amgen Subsidiary Immunex's Patents Claiming Antibodies to the IL-4 Receptor
Feb 14, 2019 09:30AM Regeneron Announces Upcoming Investor Conference Presentation
Feb 11, 2019 07:07AM Sanofi (SNY) and Regeneron (REGN) to Offer Praluent at 60% Discount
Feb 11, 2019 07:00AM Sanofi and Regeneron offer Praluent® (alirocumab) at a new reduced U.S. list price
Feb 11, 2019 06:59AM Regeneron and Sanofi Offer Praluent® (alirocumab) at a New Reduced U.S. List Price
Feb 11, 2019 05:44AM Regeneron (REGN) Announces 1-Yr. Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium
Feb 9, 2019 04:30PM One-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium
Feb 6, 2019 06:30AM Regeneron Reports Fourth Quarter and Full Year 2018 Financial and Operating Results
Feb 4, 2019 05:57AM UPDATE: Sanofi (SNY), Regeneron (REGN) Report CHMP Recommends Approval of Praluent (alirocumab) to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease
Feb 4, 2019 01:01AM Sanofi: CHMP recommends approval of Praluent® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease
Feb 4, 2019 01:01AM Sanofi: CHMP recommends approval of Praluent® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease
Feb 4, 2019 12:59AM CHMP Recommends Approval of Praluent® (alirocumab) Injection to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease
Jan 23, 2019 12:01PM Forty of the Nation's Most Brilliant Young Scientists Named Finalists in Regeneron Science Talent Search 2019
Jan 18, 2019 04:01PM Regeneron to Report Fourth Quarter and Full Year 2018 Financial and Operating Results and Host Conference Call and Webcast on February 6, 2019
Jan 7, 2019 07:00AM Regeneron Provides Update on Commercial and Pipeline Progress at J.P. Morgan Healthcare Conference
Jan 7, 2019 05:59AM Regeneron (REGN), Sanofi (SNY) Report Restructuring of Immuno-Oncology Collaboration for Discovery and Development Programs
Jan 7, 2019 02:31AM Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
Jan 7, 2019 02:30AM Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
Jan 7, 2019 02:30AM Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
Dec 18, 2018 04:01PM Regeneron Announces Presentation at the 37th Annual J.P. Morgan Healthcare Conference
Dec 3, 2018 08:52AM Regeneron (REGN) Reports Positive Phase 1 REGN1979 Data at ASH
Dec 1, 2018 12:00PM Regeneron Presents Positive Data at ASH for REGN1979 CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Nov 20, 2018 05:00PM Regeneron Announces Upcoming Investor Conference Presentation
Nov 12, 2018 06:17AM Regeneron (REGN), Sanofi (SNY) Report New Analyses from ODYSSEY OUTCOMES Trial for Praluent (alirocumab) Injection
Nov 11, 2018 08:15AM ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) Injection was associated with fewer deaths from any cause
View More Recent Stories View Older Stories